

Index

Note: Page numbers followed by ‘b’, ‘f’ and ‘t’ refer to boxes, figures and tables, respectively.

- age-standardised incidence (or morality rate) (ASR), calculation of, 3
- body mass index (BMI)
 - and endometrial cancer, 118
 - and laparoscopic surgery, complications of, 84, 86
 - and ultrasound (US) limitations, 23
- cancer datasets for cancer staging, patient management and prognosis, 22
- cancer of female genital tract
 - and endometriosis, 21
 - management of by pathologists, 11–13
- cancer screening. *See also screening of individual cancers*
 - calculation of sensitivity, specificity and predictive value of screening test, 4–5, 5t
 - definition of, 4
 - screening test performance, 4–5
- cervical cancer. *See also* cervical intraepithelial neoplasia (CIN)
 - aetiology of, 9
 - HPV and pre-invasive cervical disease, 63
 - HPV as factor in, 9
 - incidence and morality of in UK vs. world, 8–9
 - prevalence of in UK, and developed countries, 127
- cervical cancer, diagnosis and investigation of
 - baseline blood tests for, 128
 - determination of parametrial involvement, 131
 - diagnosis by tissue biopsy, 128
 - examination of cervix with speculum, 128
 - examination under anaesthetic and clinical staging, 129–131
 - post-coital bleeding, post-menopausal bleeding as symptoms, 127, 128
 - signs and symptoms, 127–128
 - squamous epithelium thickness, lack of maturation in, as symptom, 14f
 - symptoms in late stages, 127
- cervical cancer, diagnostic imaging in
 - diagnosis by biopsy, CT, 27
 - diagnostic imaging in cancer recurrence, modalities used in, 29
 - image of MRI cervix and PET/CT of nodal disease, 129f
 - imaging of lymph nodes, 128–129
 - magnetic resonance imaging (MRI) and radiotherapy planning, 29
 - magnetic resonance imaging (MRI) for assessing optimal brachytherapy position, 29
 - magnetic resonance imaging (MRI) for identifying complications, 29
 - magnetic resonance imaging (MRI) for staging investigation, 27, 28, 28f, 39
 - pelvic MRI imaging for stage IIb cervical cancer, 28
 - radiology in staging tumour, 27–29
 - repeated imaging and chemoradiation in treatment of advanced disease, 29
- cervical cancer, pathology of
 - histological features of, 127
 - spread of cervical cancer to organs, 130
 - squamous cell carcinoma, adenocarcinoma, 127
- cervical cancer, prevention and screening for
 - HPV DNA testing, 63
 - HPV testing and cervical cytology, 63
 - HR HPV testing, compared to cytology, 63
 - MRI for staging investigation, 39
 - NHS Cervical Screening Programme (NHSCSP), 63–64
 - NHS Cervical Screening Programme (NHSCSP), management guidelines, 63
 - prevention of with HPV screening, HPV vaccine, 9
 - screening, importance of, 127
- cervical cancer, staging of
 - clinical staging, 129–131
 - diagrammatic representation of staging for cervical cancer, 130f
 - FIGO staging for carcinoma of the cervix, 204b
 - 5-year survival rates by stage, 44, 136
 - magnetic resonance imaging (MRI) for staging investigation, 27, 28, 28f, 39
 - pelvic MR imaging for stage IIb cervical cancer, 28
 - stage I, 28, 43–44
 - stage II, 28, 44
 - stage III, 26, 44
 - stage IVA, local invasion of bladder or bowel, 28, 44
- cervical cancer, surgical management of. *See also* cervical cancer, treatment of
 - cone biopsy, 131–132
 - fertility-sparing surgery, 132
 - pelvic lymph node dissection, 132
 - radical hysterectomy, 132
 - radical trachelectomy, 132
 - sentinel lymph node mapping in cervical cancer surgery, 132
- cervical cancer, treatment by stage. *See also* cervical cancer, treatment of
 - adjuvant treatment post-surgery with chemoradiotherapy, for stage IB2 to stage IIIB, stage IV, 131
 - combined external beam radiotherapy and brachytherapy as treatment for stage Ib1, small volume IIa, 44
 - hysterectomy and lymphadenectomy as treatment for stage Ib1, small volume IIa, 44
 - laparoscopic surgery for early-stage disease, 86
 - large loop excision of transformation zone (LLETZ) as treatment for Stage Ia1 in younger patients, 43
 - radiotherapy with chemotherapy as treatment for stage Ib2, IVa, or locally advanced disease, 44
 - stage IA1, 131
 - stage IA2, 131
 - stage IB1, range of tumours, 131
- cervical cancer, treatment of
 - adjuvant radiotherapy for women with node-positive disease, 39
 - adjuvant radiotherapy, chemoradiotherapy for recurrence, 45
 - adjuvant treatment, 133
 - cervix brachytherapy, 46f
 - exenterative surgery for recurrence, 39
 - hysterectomy and pelvic lymph node dissection for stage IB1, 39
 - laparoscopic surgery for, 95–96
 - neoadjuvant chemotherapy, 133
 - ovarian transposition, in in vitro fertilization, 133
 - palliative care, 39
 - pan-aortic radiotherapy, survival rates of, 44
 - pelvic radiotherapy, and loss of fertility, 133
 - primary chemoradiotherapy, 133
 - psychosexual counselling in, 39
 - radical radiotherapy and chemo for stage IB2 and above, 39
 - radical surgery, 39
 - radiotherapy, 39

Index

- cervical cancer, treatment of (*cont.*)
 radiotherapy, planning of, 40
 recurrence, determining risk of, 45
 superior technique of IMRT allowing
 the dose prescribed to be tightly
 conformed to the target volume, thus
 sparing the organs at risk, 45*f*
 time of completion, importance of with
 radical chemoradiotherapy, 39
- cervical intraepithelial neoplasia (CIN)
 classification of, 62–63
 definition of, 62
 grading system of, 62–63
 and HPV, 64
 and progression of oncogenic HPV
 infection, 64
 risk factors of, 62
- chemotherapy. *See also Systemic therapy and
 chemotherapy for individual cancers*
 CHORUS (chemotherapy or upfront
 surgery) trial, 60
 cytotoxic chemotherapy, basic
 principles of, 52
 myelosuppression, as side effect of
 chemotherapy, 60
 neoadjuvant chemotherapy (NACT), 60
 post-surgery chemotherapy, 60
 sepsis, risk of from chemotherapy, 60
 toxicities of, 52–53
- chemotherapy, specific agents of
 angiogenesis inhibitors, 55–56
 anthracyclines, 54
 anti-metabolites, 55
 anti-microtubule agents (taxanes), 53–54
 anti-tumour antibiotics, 55
 bevacizumab, administration and mode
 of action of, 55–56
 bevacizumab, adverse effects of, 56
 bevacizumab, therapeutic uses of, 56
 biological agents, 55–56
 bleomycin, administration and mode of
 action of, 55
 bleomycin, adverse effects of, 55
 bleomycin, therapeutic use of, 55
 carboplatin and cisplatin, administration
 and mode of action of, 53
 carboplatin and cisplatin, adverse effects
 of, 53
 carboplatin and cisplatin, therapeutic
 uses of, 53
 doxorubicin (adriamycin) and pegylated
 liposomal doxorubicin (PLD),
 administration and mode of
 action of, 54
 doxorubicin (adriamycin) and pegylated
 liposomal doxorubicin (PLD), adverse
 effects of, 54
 doxorubicin (adriamycin) and pegylated
 liposomal doxorubicin (PLD),
 therapeutic uses of, 54
 gemcitabine, administration and mode of
 action of, 55
 gemcitabine, adverse effects of, 55
 gemcitabine, therapeutic uses of, 55
 niraparib and olaparib, administration
 and mode of action of, 56
 niraparib and olaparib, adverse effects
 of, 56
 niraparib and olaparib, therapeutic uses
 of, 56
 paclitaxel and docetaxel, administration
 of and mode of action of, 53
 paclitaxel and docetaxel, adverse effects
 of, 53–54
 paclitaxel and docetaxel, therapeutic uses
 of, 54
 PARP inhibitors, 56
 platinum agents of, 53
 topoisomerase inhibitors, 54–55
 topotecan and etoposide, administration
 of, 55
 topotecan and etoposide, adverse effects
 of, 55
 topotecan and etoposide, mode of action
 of, 54
 topotecan and etoposide, therapeutic
 uses of, 55
- choriocarcinoma. *See also gestational
 trophoblastic disease (GTD)*
 epidemiology, origin and pathology of,
 160–161
 symptoms of, 161
- choriocarcinoma, diagnosis and
 investigation of
 diagnosis and investigation, management
 in, 162
 MRI scan showing multiple brain
 metastases with haemorrhage
 before and after central nervous
 system (CNS)-modified etoposide,
 methotrexate and actinomycin D/
 cyclophosphamide and vincristine
 (EMA/CO) chemotherapy, 162*f*
- clinical drug trials
 Phase 0 trials, 197
 Phase I trials, 197
 Phase II, 197
 Phase III, 197
 Phase IV, 197
- communication in gynaecological
 oncology
 ABCDE mnemonic for breaking bad
 news, 192, 193*t*
 aids to communicating evidence for
 decision-making about anticancer
 therapy in the palliative setting, 194*b*
 aids to discussing transitions from
 curative to palliative care, 194*b*
 barriers in diagnosing ‘dying’, 195*b*
 breaking bad news, and five stages of
 grief, 192–193
 breaking bad news, pitfalls of, 193
 breaking bad news, tools for, 192–193
 communication training, 192
 dialogue between doctors, patients, 191
 end-of-life communication, 194–196
 end-of-life communication, desired
 results of, 194*b*
 information exchange between doctors,
 patients, 191–192
 internal conflict of patient, complications
 of, 192
- multi-disciplinary teams (MDTs), role of,
 188–189
- National Cancer Patient Experience
 Survey on information needs of
 patients, 193
- patient-reported communication needs
 and information requests, 193–194
- SPIKES model for breaking bad news,
 192, 193*t*
- Cowden syndrome (CS)
 in endometrial cancer, 113
- cumulative incidence, 3
- decision-making in gynaecological
 oncology
 in adjuvant treatment, 36
 decision-making approaches in
 gynaecological oncology, 36, 37*b*
 and genetic testing, 74
 and local vs. systemic treatment, 36–37
 in palliative treatment, 36, 109
 in radical/curative treatment, 36
 treatment and patient factors, 37
 tumour factors, as treatment
 consideration, 37
- diagnosis and investigation of malignancies.
 *See also diagnosis and investigation of
 individual cancers*
 examination steps, 11–13
 frozen section analysis in, 13
 and lymph node involvement, 12–13
 lymphovascular invasion, examination
 of, 12
 and tumour grade, 12
 and tumour stage, 12
 and tumour types, 12
 vascular invasion, examination of, 12
- diagnostic imaging. *See also diagnostic
 imaging for individual cancers*
 computerised tomography, phases of,
 24–25
 for diagnosis, treatment planning and
 follow-up, 23–40
 magnetic resonance imaging (MRI),
 conventional imaging sequences of,
 23–24
 magnetic resonance imaging (MRI),
 limitations of, 24
 positron emission tomography (PET),
 with computerised tomography, 25
 ultrasound (US) limitations in patients
 with large body mass index
 (BMI), 23
- disability-adjusted life-years (lost),
 calculation of, 4
- doll, Sir Richard, 3
- endometrial cancer. *See also endometrial
 hyperplasia*
 aetiology of, 8, 112
 age and risk of recurrence of, 47
 Cancer Genome Atlas (TCGA) project
 classification of, 46
 classification of by World Health
 Organization (WHO), 115, 115*t*
 and Cowden syndrome (CS), 76, 113

- criteria to identify high risk families of breast, ovarian cancer/endometrial cancer, 73*t*
- cure rate for, 46
- and fertility preservation, 186
- GOG definition of high-intermediate risk, 47
- as hereditary cancer, 71
- high dose oral progesterone and/or locally delivered progesterone for early-stage type I, 186
- incidence and mortality rates in UK vs. world, 6
- and Lynch syndrome (LS), 76, 112–113
- malignant progression of, 112
- obesity and diabetes as risks for, 8
- oestrogens and progestins, role of in malignant transformation, 8
- relapse risk of, 118
- in women under 45 years of age, 186
- in women under 50 years of age, 113
- endometrial cancer, diagnosis and investigation of. *See also* endometrial cancer, staging of
- abnormal non-cervical glandular cells on cervical smear as sign of endometrial abnormality, 113
- algorithm for assessment of post-menopausal bleeding, 114*f*
- characteristics of type 1 and type 2 endometrial cancer, 17*t*
- clinical history and examination of, 118
- endometrial thickness as diagnosis marker, 25, 114
- five-year survival following diagnosis of endometrial cancer, 125*t*
- NICE guidelines, 113
- postmenopausal bleeding as warning sign of, 25, 113–114
- pre-operative investigation of, 118–120
- prognosis factors, 124–125
- referral guidelines and diagnostic testing, 113–114
- symptoms of, 113
- tamoxifen as cause of benign symptoms, 114
- trans-vaginal ultrasound scan as initial diagnostic tool, 114
- endometrial cancer, diagnostic imaging in computerised tomography (CT), role in advanced disease, 27
- CT imaging for patients at high risk of recurrence, 27
- diagnosis using high-resolution imaging with transvaginal ultrasound (TVUS), 25
- MRI imaging in endometrial cancer, 25–26, 26*f*
- MRI scan for pre-treatment evaluation of endometrial cancer, 120*f*
- pre-operative imaging in management of endometrial cancer, 118–120
- endometrial cancer, pathology of
- haematogenous spread, 116
- lymphatic spread to lymph nodes, 116
- metastasis, 116
- trans-tubal spread to fallopian tubes, 116
- type I tumours, in early-stage diagnosis, 115
- type II tumours, in higher-stage diagnosis, 115
- endometrial cancer, prevention and screening of
- population screening for endometrial cancer, in asymptomatic women, 116
- risk factors associated with, 8*t*
- risk factors for endometrioid endometrial cancers (EEC), 112
- and risk for VTE, 124
- risk-reducing surgery for women with genetic predisposition, 116
- screening for women with genetic predisposition, history of Lynch syndrome, 116
- and smoking as risk factor, 112
- endometrial cancer, staging of
- AJCC (American Joint Committee on Cancer Tumour, Node, Metastasis System) for, 116
- FIGO Staging for Carcinoma of the Corpus Uteri, 202*b*
- FIGO System (International Federation of Obstetrics and Gynaecology) for, 116
- stage I, 26
- stage IIIa, IIIb, IIIc, 26
- stage IV, 26–27
- staging system for endometrial cancer, 25–27, 48
- endometrial cancer, treatment of
- adjuvant chemotherapy, 38
- adjuvant external beam radiotherapy, dose fractionations for, 49
- adjuvant radiotherapy for high-intermediate risk patients, 47
- adjuvant radiotherapy for stage II, 38–39
- adjuvant therapy for, 47
- adjuvant treatment for advanced disease, 123
- adjuvant treatment for early-stage disease, 123–124
- for advanced disease, 121
- chemotherapy agents used in, 124
- endometrial ablation, as contraindicated for, 118
- external beam radiotherapy with a brachytherapy boost for stage II disease, 47–48
- fertility-sparing treatment for, 124
- fertility-sparing treatment, inefficacy of, 118
- field borders for conformal radiotherapy treatment, 48
- high-risk disease, recommendations for treatment, 48
- hormonal therapy in palliative treatment for recurrent or advanced disease, 124
- hysterectomy for stage II, 38
- hysterectomy with bilateral salpingo-oophorectomy, as treatment, 47
- intra-operative complications of, 121
- laparoscopic surgery for, 96, 121
- laparoscopic surgery for early-stage disease, 86
- levonorgestrel intrauterine system as fertility-preserving treatment, 118
- lymphadenectomy for, 38, 121
- modern high dose rate (HDR) brachytherapy for early-stage endometrial cancer, 43
- neo-adjuvant chemotherapy for, 124
- for obese women, 96
- omentectomy/omental biopsy in, 38, 121
- out-patient hysterectomy for, 114*f*
- palliative care treatment, 39
- palliative treatment for recurrent disease, 124
- para-aortic radiotherapy, 49
- Post-Operative Radiation Therapy in Endometrial Cancer (PORTEC) criteria for high-intermediate risk, 47
- radiotherapy as primary treatment, 46–49
- radiotherapy types in treatment of endometrial cancer, 122
- radiotherapy, side effects and complications of, 123
- radiotherapy/chemotherapy for women with recurrent and advanced disease, 39
- removal of uterus, cervix, fallopian tubes and ovaries in, 38
- risk of adjuvant treatment, 47
- surgery as treatment of low-risk disease, 47
- surgical complications in, 121–122
- vaginal brachytherapy as sole adjuvant treatment, 49
- vaginal brachytherapy for stage IB disease, 47–48
- endometrial hyperplasia
- algorithm for treatment of atypical endometrial hyperplasia (AH), 119*f*
- classification system for, 68
- endometrial hyperplasia with atypia, and risk of developing cancer, 69–70
- endometrial hyperplasia with atypia, investigation and treatment of, 69–70
- endometrial hyperplasia without atypia, 69
- epidemiology of, 68–69
- hysterectomy as treatment for, 69
- hysterectomy for atypical hyperplasia, 118
- management of, 69*f*, 117–118
- epidemiology
- description of, 1
- in public health, 1
- gestational trophoblastic disease (GTD)
- β-hCG as tumour marker, 156
- CHM diagnosis and investigation, steps for, 158
- CHM, PHM and serial hCG monitoring, 158
- CHM, PHM symptoms, 157

Index

- gestational trophoblastic disease (GTD) (*cont.*)
 FIGO staging for trophoblastic tumour, 206*b*
 GTD and registration in UK, 158
 human chorionic gonadotrophin (hCG) production and GTD, 157
 hydatidiform moles (CHM and PHM), epidemiology, origin and pathology of, 157–158
 hydatidiform moles, description of, 157
 procedures for molar pregnancy, 158
 serial hCG and tumour marker for, 157
 gestational trophoblastic disease (GTD), treatment of
 chemotherapy for, 159
 chemotherapy for high-risk disease, 160
 chemotherapy for low-risk disease, 159–160
 FIGO prognostic scoring system for GTD post-treatment, 160*t*
 graph of hCG in patient with low-risk disease, 161*f*
 management of specific complication of, 163–164
 pelvic ultrasound showing large gestational trophoblastic tumour that developed after molar pregnancy and chemotherapy, 159, 160*f*
 prognosis and follow-up of, 164
 prognosis of, 163
gynaecological cancer, staging of. *See also staging of individual cancers*
 FIGO clinical staging, rules for, 198–199
 metastasis, staging of, 201*b*
 regional lymph nodes, staging of, 200*b*
 TNM system, 199–200
gynaecological cancers. *See also entries for individual cancers*
 classification of by International Classification of Diseases for Oncology (ICD-O-3), 2
 classification of by International Statistical Classification of Diseases and Related Health Problems, 1
 five ways to well-being of women living with long-term disease, 177
 incidence rate of, 3
 morphological classification of malignant neoplasms of female genital organs, 2*t*
 ten most common causes of cancer deaths of women in UK, 2014, 198*f*
 treatment approaches in, 34–40
 twenty most common cancer in UK in 2014, 198*f*
hereditary gynaecological cancers. *See also* Lynch syndrome (LS)
 Cowden syndrome (CS), and breast cancer, endometrial cancer, 76
 criteria to identify high risk families of breast, ovarian cancer/endometrial cancer, 73*t*
 and determining risk using family history, 71
 diagnostic genetic testing compared to predictive genetic testing, 72
 diagnostic genetic testing, as advocated by international bodies, 72
 genetic evaluation of ovarian tumours, 75
 genetic testing and decision-making process, 74
 genetic testing for, 71
 genetic testing for BRCA1/BRCA2 mutations in Ashkenazi Jews in UK, 72
 genetic testing for ovarian cancer in high-risk women, lack of programs for, 74
 hereditary breast and/or ovarian cancer syndromes, 72
 hereditary ovarian cancers and BRCA and BRCA2 mutations, 72
 moderate risk genetic mutations for hereditary ovarian cancers, 73
 and percentage of ovarian cancer, endometrial cancer, 71
 Peutz-Jeghers Syndrome, 76
 risk-reducing salpingo-oophorectomy (RRSO) for risk of ovarian cancer, 74
 risk-reducing strategies for hereditary cancers, 74–75
 risk-reducing surgery for genetic predisposition for endometrial cancer, 116
 summary of hereditary gynaecological cancers, 72*t*
 syndromes of, 71
hormonal therapies for gynaecological cancers
 anastrozole and letrozole, administration and mode of action of, 57
 anastrozole and letrozole, adverse effects of, 57
 anastrozole and letrozole, therapeutic uses of, 57
 aromatase inhibitors, 57
 medroxyprogesterone acetate and megestrol acetate, administration and mode of action of, 57
 medroxyprogesterone acetate and megestrol acetate, adverse effects of, 57
 medroxyprogesterone acetate and megestrol acetate, therapeutic uses of, 57
 oestrogen receptor modulators, 56–57
 progestogens, 174
 tamoxifen adverse effects of, 57
 tamoxifen, administration and mode of action of, 56
 tamoxifen, dosing of, 56
 tamoxifen, therapeutic uses of, 57
human papillomavirus (HPV)
 and anal intraepithelial neoplasia (AIN), 126
 in cervical and vaginal tumours, 126
 in cervical cancer, 9, 64
 and cervical intraepithelial neoplasia (CIN), 126
 and development of CIN, 64
 genome comprisal of, 126
 HPV testing and cervical cytology, 63
 NHSCSP Colposcopy and Programme management guidelines for HPV DNA testing, 63
 in pathology of gynaecological cancers, 11
 and pre-invasive cervical disease, 62
 and smoking, 64
 vaccination programme in UK, 64, 127
 vaccine and cancer reduction rates, 127
 vaccine for, 64
 and vaginal cancer, risk of, 49, 126–127, 134
 and vaginal intraepithelial neoplasia (VAIN), 126
 vulval cancer and prevalence of HPV infection, 146
 and vulval cancer, pathology of, 139–140
 and vulval intraepithelial neoplasia (VIN), 126
incidence rate. *See also incidence rates of individual cancers*
 definition of, 3
 frequency distribution (%) of the 22 most common cancers in women, England 2003–2007, 6*f*
 partial (or limited duration) incidence, mathematical equation of, 31
 trends in UK, 6
 use in gynaecological oncology, 3, 5
informed consent
 and multi-disciplinary meetings (MDTMs), 190
 patient's capacity for, 190–191
 pre-requisites for, 190
laparoscopic surgery
 advantages of, 86
 and BMI as special consideration, 85–86
 and BMI, risk of complications with, 84
 for cervical cancer, 95–96
 and early-stage endometrial and cervical cancer, 86
 electrosurgery devices for, 84*f*
 for endometrial cancer, 96
 energy devices for minimal access and open surgery, principles of, 84–85
 energy devices for, types of, 84–85
 energy devices, complications of, 85
 entry techniques and incisions, 83
 equipment for, 88
 ergonomics of setup for, 88
 fertility-sparing approaches in gynaecologic oncology, 86*t*
 laparoscopy and avoidance of diathermy, 94
 laparoscopy and BMI-related complications, 94
 laparoscopy and risk of conversion to laparotomy, 90
 laparoscopy, anaesthetic considerations for, 92
 laparoscopy, avoiding complications and injury from, 93–94
 laparoscopy, complications of, 92–94
 laparoscopy, energy sources for, 85

- laparoscopy, establishment of
 - pneumoperitoneum and primary port placement for, 90–91
- laparoscopy, positioning of patient for, 90
- laparoscopy, post-operative programme for, 86
- laparoscopy, range of equipment for, 91
- laparoscopy, rate of complications from, 92
- laparoscopy, recovery time from, 92
- laparoscopy, special considerations for, 94–95
- primary and accessory port site placement in relation to vessels of anterior abdominal wall, 84*f*
- and rate of post-operative adverse events, 86
- relationship between bifurcation of aorta and umbilicus in normal body weight and obesity, 86*f*
- vs. robotic surgery, 86
- robotically-assisted laparoscopic surgery, 95
- role of laparoscopic surgery in gynaecological cancers, 86
- transperitoneal para-aortic node dissection, 96*f*
- laparoscopy. *See entries under Laparoscopic surgery*
- living with gynaecological cancer
 - Cancer Recovery Package, as strategized by Independent Cancer Taskforce, 182–183
 - cancer survivor, definition of by Macmillan Cancer Support, 181
 - five-year strategy for cancer services, by Independent Cancer Taskforce in UK, 182
 - holistic care, as part of cancer services, 184
 - Holistic Needs Assessment (HNA), role of in management and care, 183
 - and infertility, 186
 - Macmillan Cancer Support, role of in UK, 181
 - Macmillan/NCIN simplified survivorship outcome framework, 181
 - NHS Recovery Package, as support for individuals living with cancer, 182
 - Patient Reported Outcome Measures (PROMS) questionnaire, and quality of life, 184
 - Patient Reported Outcome Measures (PROMS) questionnaire, restrictions of, 183
 - and quality of life as multidimensional concept, 185
 - quality of life, measurement of in clinical trials, 185
 - and sexuality, 184–185
 - survival, length and complexity of as defined by Macmillan Cancer Support, NCIN, 181
 - and survivor framework, 182
 - survivorship pathways, 181–182
- lymphoedema
 - assessment of, 185
 - incidence of in cancer survivors, 185
 - management of, 185
 - and quality of life, 185
- Lynch syndrome (LS)
 - Amsterdam II guidelines for clinical diagnosis of, 113*b*
 - in endometrial cancer, 76, 112–113
 - and hereditary disease, 75–76
 - in ovarian cancer, 76
 - revised Bethesda guidelines for identification of patients for whom microsatellite instability (MSI) testing is warranted, 113*b*
 - screening for women with genetic predisposition, history of Lynch syndrome, 116
- malignant germ cell tumours
 - in premenopausal, postmenopausal women, 153
 - tumour types, 153
- malignant germ cell tumours, diagnosis and investigation of
 - symptoms of, 154
 - tumour markers, 154
- malignant germ cell tumours, treatment of
 - fertility-sparing surgery, 154
 - follow-up requirements for, 155
 - neoadjuvant chemotherapy in, 154–155
 - for relapsed disease, 155
 - for stage IA/B disease, 154–155
 - for stage IC and above disease, 155
 - surgery for complete tumour resection and staging, 154
- markers used in diagnosis, management and prognostication of tumours
 - diagnostic immunohistochemistry (IHC), 22
 - markers to aid management of tumours, 22
 - molecular pathology for diagnosis, treatment, prognostication of tumours, 22
- metastatic tumours, 20–21
- minimal access surgery (MAS). *See also* laparoscopic surgery
 - and conversion to laparotomy, risk of complications from, 90
 - pre-operative factors to consider, 89
- molar pregnancy. *See* gestational trophoblastic disease (GTD)
- mortality. *See also* survival
 - cancer mortality rates, 4
 - definition of, 4
- multi-disciplinary team (MDT)
 - clinical management decisions by, 188–189
 - communication, importance of, 188–189
 - definition of by NHS, 188
 - improving the effectiveness of multidisciplinary team meetings in cancer services, 189*b*
 - key components of, 189*b*
 - MDT meetings (MDTM), role of, 188–189
- non-epithelial ovarian tumours,
 - classification of, 153, 153*t*
- ovarian cancer
 - aetiology of, 6
 - average number of new cases per year and age-specific incidence rates per 100,000 population in UK, 98*f*
 - criteria to identify high risk families of breast, ovarian cancer/endometrial cancer, 73*t*
 - early detection of in UK, strategies for, 29
 - epithelial ovarian cancer (EOC) in
 - women with hereditary nonpolyposis colon cancer (HNPCC) syndrome, 100
 - epithelial ovarian cancer (EOC),
 - description of, 98
 - and fertility preservation for patients with stage IA epithelial ovarian cancer, 186–187
 - genetic evaluation of ovarian tumours, 75
 - genetic testing in high-risk women, lack of programs for, 74
 - as hereditary cancer, 71, 99
 - hereditary ovarian cancer syndromes, 72
 - hereditary ovarian cancers and BRCA and BRCA2 mutations, 72, 99, 99*t*
 - and Lynch syndrome (LS), 76
 - moderate-risk genetic mutations for hereditary ovarian cancers, 73
 - protective factors of ovarian cancer, 99*t*
 - recurrence, risk of, 32–33, 110
 - recurrent disease, classification of, 107–108
 - Risk of Malignancy Index (RMI), 102*t*
 - risk rates of, 98
 - survival rates in UK vs. Canada, Australia, Norway, Sweden, 98
 - theories on association between ovarian cancer and number of ovulation theory, 98–99
- ovarian cancer, diagnosis and investigation of. *See also* ovarian cancer, staging of
 - borderline ovarian tumours, clinical presentation and diagnoses of, 109
 - by computed tomography (CT), 102
 - flow diagram of investigation and management, 103*f*
 - investigation, components of, 101
 - NICE Guidance recommendation of investigation with tumour marker Caner Antigen 125 (CA125), 101
 - oral contrast to identify serial disease, 31
 - RCOG Greentop Guideline 34
 - recommendations for investigation, 101
 - tumour markers for diagnosis, 101–102
 - typical symptoms, 101
 - ultrasonography, 102
 - USS classification system to differentiate benign and malignant factors, 102, 102*t*
- ovarian cancer, diagnostic imaging in
 - computerised tomography (CT), 30–31
 - computerised tomography (CT), as primary staging method, 31

Index

- ovarian cancer, diagnostic imaging in (*cont.*)
 - CT image following administration of intravenous contrast medium, 31, 32*f*
 - magnetic resonance imaging (MRI) to characterize masses, 31
 - pelvic ultrasound, 29–30
 - PET/CT for demonstrating tumour recurrence, 33
 - PET/CT imaging, 31
 - ultrasound (US) imaging of ovarian cancer, 29–30
- ovarian cancer, palliative care for
 - bowel obstruction as complication in, 108
 - decision making in, 109
 - measures used to reduce vomiting, 108
 - medications for symptom relief, 109
- ovarian cancer, pathology of
 - borderline ovarian tumours (BOT) *vs.* low-grade ovarian carcinomas, 109
 - borderline ovarian tumours, clinical presentation and diagnosis of, 109
 - borderline ovarian tumours, pathological features of, 109
 - clear cell tumours, 100
 - endometrioid tumours, 100
 - high-grade serous ovarian carcinoma (HGSOC) and fallopian tube hypothesis, 100–101
 - metastases, 100
 - mucinous borderline tumours, 109
 - mucinous tumours, 100
 - serous borderline tumours, 109
 - serous ovarian carcinomas (SOC), 100
- ovarian cancer, prevention and screening for
 - BRCA carriers, limited benefits of screening of, 99
 - BRCA mutations, screening for, 99
 - in general population, 100
 - and mortality rates, 70
 - prevention of, 6–7
 - risk-reducing early salpingectomy with delayed oophorectomy (RRESDO), for epithelial ovarian cancer, 75
 - risk-reducing salpingo-oophorectomy (RRSO) for women at risk, 74
 - risks for, 3
- ovarian cancer, staging of
 - ascites as predictor for stage IIIB/C, 32
 - computerised tomography (CT), as primary staging method, 31
 - diagrammatic representation of staging for ovarian cancer, 104*f*
 - FIGO staging for carcinoma of the ovary, 200–203
 - FIGO system, use of, 31, 104
 - malignant ovarian germ cell tumours, as stage I cancer in women below 20 years of age, 187
 - pleural effusion for detection of stage IVA, IVB, 32
 - radiological and histological staging using CT imaging, 104–105
 - stage I, 31
 - stage II, 31
 - stage III, 31
 - stage IIIA, B, C, 31–32
 - staging and surgery for advanced ovarian cancer, 105
 - staging surgery for suspected stage, elements of, 105
 - widespread military deposits in case of advanced ovarian cancer, 105*f*
- ovarian cancer, treatment of
 - bevacizumab, as anti-angiogenic agent for advanced-stage epithelial ovarian, fallopian tube and primary peritoneal cancers, 61
 - chemotherapy for advanced-stage disease, 107
 - chemotherapy for early-stage disease, 107
 - chemotherapy for recurrent disease, 107–108
 - chemotherapy, description of, 38
 - consolidation and maintenance therapy for recurrent disease, 108
 - cytoreductive surgery (CRS), 38
 - cytoreductive surgery (CRS) for advanced disease, procedure and terms for, 105–106
 - cytoreductive surgical approach combined with chemotherapy, approaches to, 106–107
 - fertility-sparing procedures, option for patients with borderline tumours, non-epithelial ovarian cancers, and early-stage 1A epithelial ovarian cancers, 108
 - fertility-sparing surgery, elements of, 108
 - histological confirmation in, 38
 - hyperthermic intraperitoneal chemotherapy (HIPEC), 107
 - midline incision in non-early stages, use of, 38
 - palliative chemotherapy in, 38
 - palliative radiotherapy in, 38
 - primary surgery in, 38
 - radical surgery for stage IV, 38
 - recurrence rates after chemotherapy, 107–108
 - risk-reducing surgery for BRCA carriers, 99–100
 - secondary cytoreductive surgery for recurrent disease after primary treatment, 38
 - surgery and systemic therapy in, 60
 - surgery for recurrent disease, 108
- ovarian sex cord stromal tumours and genetic mutations, 155
- histopathology diagnosis of, 155
- ovarian sex cord stromal tumours, diagnosis and investigation of
 - association of granulosa cell tumours and complex atypical hyperplasia or carcinoma of the endometrium, 156
 - symptoms of, 155
 - tumour markers, 156
- ovarian sex cord stromal tumours, treatment of
 - adjuvant treatment, 156
 - of recurrent disease, 156
 - surgical management in, 156
- palliative care. *See also palliative care for individual cancers*
 - anxiety and depression, approach to, 175
 - breathlessness, management of, 175
 - complex fungating and malodorous wounds, management of, 174
 - constipation, management and prevention of, 172–173
 - definition of, 165
 - end of life phase in, 177–178
 - hypercalcaemia, careful considerations for, 173–174
 - hypercalcaemia, diagnosis and symptoms of, 173
 - hypercalcaemia, treatment of, 173
 - and nausea/vomiting, 171
 - nausea/vomiting, other causes of, 171
 - outline of generalist and specialist care aspects of problems typical of those occurring in women with gynaecological malignancies: the generalist palliative care, 167*t*
 - pain management in, 168–170
 - pain, types of, 170
 - partial bowel obstruction, as cause of nausea/vomiting, 171
 - partial bowel obstruction, management of, 171
 - practical issues in, 175
- palliative care, drugs used in
 - anti-emetics, 171–172
 - anti-emetics acting on serotonin receptors, 172
 - anti-emetics acting principally in chemoreceptor trigger zone (CTZ), 172
 - anti-emetics acting principally in the vomiting centre in central nervous system, 172
 - antispasmodic and antisecretory anti-emetics, 172
 - broad spectrum anti-emetics, 172
 - dexamethasone, 172
 - pro-kinetic anti-emetics, 172
 - symptom control, principles of, 165
 - typical prescription for an opioid-naïve patient with partial bowel obstruction, 171–172
- palliative care, psychosocial issues in
 - alienation of patient, 176
 - anger of patient and caregiver, 176
 - breakdown of relationships, 176–177
 - carer distress and exhaustion, 176
- pathologists
 - and management of malignancies of female genital tract, 11–13
 - pathologist report for gynaecological cancers, required information for, 79
- pathology of gynaecological cancers. *See also pathologies of individual cancers*
 - genetic mutations, role of, 11
 - HPV, role of, 11
 - neoplasm, role of, 11
- patient-centred care
 - decision making in, 58

- performance status (PS), definition of, 58–59
 and quality of life, 59–60
 peritoneum tumours, 21
 pre-invasive cervical disease
 cervical glandular intraepithelial neoplasia (CGIN), features of, 14, 15*t*
 cervical glandular intraepithelial neoplasia (CGIN), treatment of, 66
 colposcopy for diagnosis of, 65–66
 cytology results of, 65
 excision biopsy, as treatment of, 66
 hysterectomy, as treatment of, 66
 management of, 65–66
 management of in special circumstances, 67*t*
 NHSCCP programme standards for management of, 65
 screening protocol algorithm and colposcopy management recommendations for CIN/GIN, 65*f*
 treatment of with large loop excision of the transformation zone (LLETZ), 66
 pre-invasive disease. *See also individual pre-invasive diseases*
 cervical intraepithelial neoplasia (CIN), definition of, 62
 cervical intraepithelial neoplasia (CIN), grading system of, 62–63
 cervical intraepithelial neoplasia (CIN), risk factors for, 62
 classification of by CIN I–III, Lower Anogenital Squamous Terminology (LAST) project, Bethesda classification, 62
 HPV and pre-invasive cervical disease, 62
 pre-invasive endometrial disease. *See* endometrial hyperplasia
 pre-invasive vaginal disease. *See* vaginal intraepithelial neoplasia (VaIN)
 pre-invasive vulvar disease. *See* vulvar intraepithelial neoplasia (VIN)
 preinvasive and neoplastic disease of the female genital tract
 pathology of, 13–17
 prevalence, definition of, 3
 complete prevalence, 4
 public health, definition of, 1
 quality of life
 elements of, 36*t*
 and living with gynaecological cancer, 184
 measurement of in clinical trials, 185
 in patient-centered care, 59–60
 and radiotherapy, 46
 quality-adjusted life-year (lost), calculation of, 4
 radiation therapy. *See* radiotherapy
 radiotherapy. *See also radiotherapy for individual cancers*
 accelerated repopulation as strategy for exploitation of radio-resistant cells, 42
 biological basis of, 42
 for hypoxic areas of tumour, 42
 modern high dose rate (HDR)
 brachytherapy for early-stage endometrial cancer, 43
 pelvic field with suggested field borders for anterior beam arrangement, 45*f*
 and quality of life, 46
 radiosensitivity of cells, factors of, 42
 radiotherapy, definition and types of, 41
 and redistribution of cells around cell cycle, 42
 for repair of sub-lethal damage, 42
 small lead multi-leaf collimators, use in shaping radiotherapy beam to fit target volume, 42*f*
 toxicities from, 46
 typical linear accelerator with added cone beam CT for image-guided radiotherapy, 41*f*
 units of radiation and dose-limiting effects, 42–43
 radiotherapy machines, 43
 serous tubal intraepithelial carcinoma (STIC)
 diagnostic criteria of, 70
 imaging of, 70
 lesions of, description, 70
 progression and prognosis of, 70
 sectioning and extensively examining the (SEE-FIM) protocol for fallopian tube histological assessment, 70
 sex cord tumours, 20
 fibroma (benign) tumours, 20
 specimen pathway
 and fixation of specimen, 21
 request form for, 78
 surgery and systemic therapy. *See also* chemotherapy
 approaches to, 60
 bevacizumab, as anti-angiogenic agent for advanced-stage epithelial ovarian, fallopian tube and primary peritoneal cancers, 61
 CHORUS (chemotherapy or upfront surgery) trial, 60
 clinical trials in, 61
 EORTC 55971 trial, 60
 interval debulking surgery (IDS), 60
 neoadjuvant chemotherapy (NACT), 60
 post-surgery chemotherapy, 60
 primary debulking surgery (PDS), 60
 in treatment of epithelial ovarian, fallopian tube and primary peritoneal cancers, 60
 surgery in gynaecological oncology. *See also* laparoscopic surgery
 abdominal incisions in gynaecological oncology surgery, 83*f*
 basics of surgical principles, 77–78*t*
 bladder injury, as inoperative complication, 79
 bowel injury, as inoperative issue, 79
 bowel preparation for, 79
 and dehydration prevention, 79
 and discussion of patient's needs and expectations, 77
 for endometrial cancer in obese women, surgery approaches to, 96
 enhanced recovery programme, 82*b*
 faecal peritonitis, as inoperative complication, 79
 and haemorrhage, 80
 and importance of knowledge of anatomical structures and individual variations, 80
 incision types, 81
 inoperative issue and complications, 79–81
 mobilization, role in surgical recovery, 80
 open abdominal incisions, risk factors of, 82
 optimization of patient requirements for pre-operative preparation, 78
 and post-operative infection, 80–81
 post-operative pain relief and control methods, 81
 pre-operative investigations to identify risk and clinical condition, 77–79
 pre-operative issues, and impact on fertility, 77
 principles to follow when making choice of approach and site of incision, 82*b*
 risk factors for post-operative complications, 81*t*
 thromboprophylaxis and thromboembolic deterrent (TED) stocking, for recovery, 81
 ureter injury, as inoperative complication, 79
 ureteric leak, as inoperative complication, 80
 venous thromboembolism (VTE), as post-operative complication, 81
 survival
 definition of, 4
 5-year survival following diagnosis of endometrial cancer, 125*t*
 5-year survival rate post-exenterative surgery for vaginal cancer, 136
 5-year survival rates of cervical cancer by stage, 44
 5-year survival rates post-treatment of vaginal cancer, 136
 ovarian cancer, survival rates of in UK vs. Canada, Australia, Norway, Sweden, 4
 pan-aortic radiotherapy for cervical cancer, survival rates of, 44
 and recurrence of vaginal cancer, 146
 relative survival, calculation of, 4
 vaginal cancer treated with radiotherapy, survival rates of, 49
 vulvar cancer, survival rates of, 50
 systemic therapy. *See also* surgery and systemic therapy
 assessment of response to, 58
 histology report, use of, 57
 radiological assessment of, 58
 single agent as basis of palliative chemotherapy, 58
 single agent vs. combination chemotherapy, 57–58

Index

- systemic therapy (*cont.*)
 standardising the assessment of tumour response, 58
 summary of the WHO and RECIST 1.1 Response Criterias, 59*t*
- teamwork. *See also* multi-disciplinary team (MDT)
 benefits of teamwork in monitoring and treatment of cancer, 34–35
 disagreement among multidisciplinary teams (MDTs), 35
 working in teams as recommendations of the Improving Outcomes Guidance by Department of Health, 34
- treatment. *See also* treatment of individual cancers
 adjuvant treatment, as line of treatment, 118–119
 approaches to, 34–40
 extent of treatment, local vs. systemic, 36–37
 palliative, as line of treatment, 36
 patient factors, as treatment consideration, 37
 radical/curative, as line of treatment, 36
 teamwork, benefits of in monitoring and treatment of cancer, 34–35
 therapeutic ratio of intended treatment for radical, adjuvant and palliative, 37
 treatment intent, importance of, 36
 tumour factors, as treatment consideration, 37
- tumour classification
 with Tumour Node Metastasis Classification of Malignant Tumours (TNM-8), 2
- tumour types and abnormalities in disease of cervix. *See also* cervical cancer
 cervical adenosquamous carcinoma, 16
 cervical glandular intraepithelial neoplasia (CGIN), 14
 cervical intraepithelial neoplasia (CIN), 14
 cervical neuroendocrine carcinoma, 16
 distinguishing CGIN from invasive carcinoma, 14
 endocervical epithelium showing crowding of nuclei with mitosis and apoptotic bodies in high-grade CGIN, 15*f*
 features of, 14
 stratified Mucinous Intraepithelial Lesion (SMILE), 14–15
- tumour types and abnormalities in disease of endometrium. *See also* endometrial cancer
 endometrial carcinoma, 16
 endometrial carcinoma type 1 and type 2, characteristics of, 17*t*
 endometrial hyperplasia, 16
 endometrial hyperplasia distinguished from endometrioid carcinoma, 16
 endometrial hyperplasia types and their microscopic features, 16*t*
 serous endometrial intraepithelial carcinoma (SEIC), 16–17
- tumour types and abnormalities in disease of vulva. *See also* vulvar cancer
 Bartholins duct and gland neoplasms, 14
 vulval extramammary Paget's disease, 14
 vulval melanoma, 14
 vulval squamous cell carcinoma (SCC), 13
- tumour types and abnormalities of the ovaries and fallopian tubes. *See also* ovarian cancer
 borderline ovarian tumours, types of, 19
 carcinomas, 18
 germ cell tumours, types of, 19–20
- tumour types and abnormalities of the uterine wall
 endometrial stromal sarcoma showing typical myometrial vascular permeation, 18*f*
 endometrial stromal tumours, 17–18
 smooth muscle tumours of the uterus, 17, 18*t*
- tumours, miscellaneous, 20
- uterine sarcomas
 epidemiology of, 147–148
 FIGO staging for uterine sarcomas, 203*b*
 histological assessment of, 147
 origin of, 147
 risk factors for, 147–148
 terminology for, 147
- uterine sarcomas, diagnosis and investigation of
 assessment of, 148
 MRI of leiomyosarcoma/MRA of benign fibroids, 150*f*
 Multidisciplinary team (MDT) review, 149
 pre-operative assessment of, 149
 symptoms of, 148–149
- uterine sarcomas, treatment of
 adjuvant treatment for uterine sarcomas, 151
 chemotherapy, 151
 hormonal treatment, 151
 pelvic radiotherapy, 151
 prognosis following treatment, 151
 surgery for disease confined to uterus, 149–150
 surgery for disease extending beyond uterus, 150
 for women diagnosed after hysterectomy, 150–151
- uterine sarcomas, tumour types in
 endometrial stromal tumours, 147
 smooth muscle tumours of uncertain malignant potential (STUMP), 148
 uterine sarcomas vs. fibroids, 148
 uterine smooth muscle tumours/leiomyosarcomas, 148
- vaginal cancer
 and HPV, 49, 126–127, 134
 pathology of, 134
 rate of diagnosis in UK, 133
 statistics of occurrence, 49
 survival rates of with radiotherapy, 49
- vaginal cancer, diagnosis and investigation of
 examination with colposcopy, vaginoscopy, vulvoscopy, 134
 investigation with cystoscopy, 134
 symptoms of, 134
- vaginal cancer, diagnostic imaging in
 CT of chest/abdomen to assess spread, evaluate lymph node involvement, 134
- vaginal cancer, prevention and screening for risk factors for, 134
 smoking as risk factor for, 134
- vaginal cancer, staging of
 diagrammatic representation of staging for vaginal cancer, 135*f*
 FIGO staging for carcinoma of the vagina, 205*b*
 lymphatic involvement by stage, 136
- vaginal cancer, treatment of
 brachytherapy in treatment of stage I tumors, 49
 chemoradiotherapy as most effective, morbidity-preventing treatment, 136
 complications of treatment, 136
 diethylstilbestrol (DES) for miscarriage avoidance, 134
 5-year survival rate post-exenterative surgery, 136
 5-year survival rates post-treatment, 136
 follow-up post-treatment, 137
 palliative treatment for stage IV, 136–137
 pelvic exenteration surgery for patients who relapse post-chemoradiotherapy, 136
 radiotherapy and chemotherapy for, 135–136
 radiotherapy for stage II–IV tumours, 49
 radiotherapy for treatment of stage I tumors, 49
 radiotherapy, side effects of, 49–50
 recurrence rate, 136
 surgical management of, 135
 survival following recurrence, 146
 vault cytology to detect recurrences, inappropriateness of, 137
- vaginal intraepithelial neoplasia (VaIN)
 biopsy to prevent invasion, 68
 treatment of, 68
- vulval cancer. *See also* vulvar intraepithelial neoplasia (VIN)
 incidence in younger population, 138
 prevalence among older population in UK, 138
 survival rates of, 50
- vulval cancer, diagnosis and investigation of
 anatomical considerations for, 138
 clinical examination criteria, 141–142
 diagnosis by needle biopsy, 39, 142
 examination under anaesthesia, 142
 importance of knowledge of anatomy of vulva in understanding spread, 138
 Keyes biopsy forceps, 142*f*
 lymphatic drainage of vulva, 139*f*
 and nerve supply, 138
 pictorial representations of vulva, helpfulness of, 142

- vulval cancer, diagnostic imaging in
 - imaging and biopsy of lymph nodes by ultrasound of MRI imaging, 142
 - imaging for distal disease, 142
- vulval cancer, pathology of
 - Bartholin's gland cancer, 141
 - basal cell carcinoma, 140
 - Breslow classification of tumour stage in melanoma based on depth of invasions, 140, 141*t*
 - chronic lymphoedema of both lower limbs, 145*f*
 - comparison of clinicopathological features between two vulval intraepithelial neoplasias, 140*t*
 - differentiated or keratinizing lesions, 140
 - HPV-related disease, 139–140
 - malignant melanoma, 140
 - Paget's disease of the vulva, 141
 - sarcoma, 141
 - squamous cell carcinoma, 139–141
 - squamous cell carcinoma of right labia, 142*f*
 - verrucous carcinoma, 140
 - in vulval intra-epithelial neoplasia (VIN), 140
 - vulvar cancer spread, types of, 143
- vulval cancer, prevention and screening for
 - and prevalence of HPV infection, 146
 - risk factors for, 138
 - strategies for screening, 138
- vulval cancer, staging of
 - diagrammatic representation of staging for vulval cancer, 139*f*
 - FIGO staging for carcinoma of the vulva, 205*b*
 - staging and level of depth of invasion, 141*t*
 - staging and spread based on International Federation of Gynecology and Obstetrics classification, 142–143
- vulval cancer, surgical treatment by stage
 - eligible criteria for sentinel lymph node (SLN) biopsy, 143
 - excision of abnormal skin for minimizing risk of further tumours, 143
 - locally advanced disease, 144
 - primary surgical treatment of the vulval lesion, 143
 - reconstructive surgical options, 144
 - sentinel lymph node (SLN) biopsy for early-stage cases, 143
 - for stages I and II, 143–144
- vulval cancer, treatment of
 - adjuvant radiotherapy for node-negative disease, 50
 - adjuvant radiotherapy for node-positive disease, 50
 - adjuvant radiotherapy for women with close surgical margins, 145
 - chemotherapy, recommendations of European Society of Gynaecological Oncology (ESGO), 145
 - complications, chronic problems from surgery, 144
 - inguino-femoral lymph node dissection (LND), 50
 - local excision in surgical treatment, 50
 - management of clinically suspicious groin nodes, 144
 - management of recurrence, 145–146 and minimization of morbidity, 144
 - neoadjuvant chemoradiotherapy for locally advanced disease, 50
 - palliative radiotherapy, doses of, 51
 - palliative resection in, 40
 - palliative surgery in, 40
 - post-operative radiotherapy for metastatic disease, 40
 - pre-operative radiotherapy and chemotherapy for advanced vulval cancer, 40
 - primary radiotherapy, 145
 - radical wide local excision in (WLE), 39
 - radiotherapy for recurrence, 40
 - radiotherapy in, 40, 50–51
 - radiotherapy technique in, 50–51
 - radiotherapy, advances in, 51
 - radiotherapy, prescribed doses of, 51
 - radiotherapy, side effects of, 51
 - sentinel node dissection to reduce risk of relapse, 40
 - surgical resection for recurrence, 40
 - treatment of groin nodes, 143
 - tumour removal in, 39
 - vulvectomy in, 50
 - wide local excision and ipsilateral sentinel node dissection or lymphadenectomy for stage I, II, 40
 - wide local excision for malignant melanoma, 40
- vulvar cancer. *See also* vulvar intraepithelial neoplasia (VIN)
 - aetiology of, 10
 - incidence and mortality trends of in UK, world, 9–10
 - prevention of with HPV vaccine, 10
- vulvar cancer, treatment of
 - right lymphocele following lymphadenectomy on the same side, 145*f*
- vulvar intraepithelial neoplasia (VIN)
 - alternative treatments of, 68
 - classification of, 66–67
 - epidemiology of, 67–68
 - histological features of, 13*t*
 - and HPV, 13
 - imiquimod cream 5% in treatment of, 68
 - local excision in treatment of, 68
 - National Guidelines on the Management of Vulval Conditions, in UK, 68
 - vulvectomy in treatment of, 68
- World Health Organization (WHO) criteria of response, 197–198
- World Health Organization (WHO) performance status classification, 197